Only one week after the FDA approved a new pill for postpartum depression, nearly 30% of St. Louis adults surveyed had heard the news. Increasing community awareness of this treatment is an important part of protecting moms, babies and families in St. Louis.
According to the CDC, 1 in 8 women who recently gave birth experience symptoms of postpartum depression, a medical condition in which a woman feels sad, anxious, and tired after giving birth. It can make it difficult for mothers to take care of themselves or their baby and, in severe cases, can even be life-threatening.
The manufacturers of the new pill, Therapeutics and Biogen Inc., say the drug, Zurzuvae (Zuranolone), could be commercially available as soon as October (NPR). The pill, taken daily for 14 days, yielded promising outcomes in two trials, with some patients benefiting in as soon as three days (FDA).
This week’s report is based on 158 responses from a panel of adult residents of St. Louis City and County surveyed from Saturday, August 12, to Monday, August 14, 2023.
Explore these data and more at iHeardSTL.
Download the infographic below to share about this topic on social media.
iHeard asked St. Louisans if they had heard about the FDA approval of the first postpartum depression pill. 29% said “yes.”
Postpartum depression is a medical condition where a woman feels sad, anxious, and tired after giving birth.